Cure8 trial brief
The study describes real-world use of a treat-to-target approach in adults with Crohn's disease and ulcerative colitis, which may influence how clinicians monitor disease and adjust therapy in routine care.
Clinicians, researchers, and adult patients interested in treat-to-target strategies and real-world IBD care implementation
The study used chart review (no extra visits) of adults with at least 24 months of records and looked primarily at the percentage of patients who received a therapeutic change within 12 weeks after objective monitoring showed active disease — a practical definition of T2T used here.
Because this is observational and retrospective, the findings describe associations and real-world implementation rather than proving causation.
Observational retrospective chart reviews can identify practice patterns and associations but cannot establish causation. Results may vary by center and depend on documentation completeness.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Real-world PSP registries can show how long people stay on vedolizumab and how it’s used alongside or compared with other advanced therapies like tofacitinib. That information can help patients and clinicians understand...
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...
Pediatric-onset IBD can behave differently than adult-onset disease. Comparing conventional versus biologic approaches in children may help clarify relative effectiveness, safety, and impacts on growth and steroid...
